Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497228 | 0.79 | NOS1 (0.41) | MLYCD | |
| SCHEMBL743585 | 0.79 | NOS1 (0.44) | MLYCD | |
| SCHEMBL1512620 | 0.78 | MLYCD (0.50) | MLYCD | |
| Hydrochloric Acid SCHEMBL16416235 | 0.77 | NOS1 (0.43) | MLYCD | |
| SCHEMBL2992212 | 0.76 | MLYCD (0.49) | MLYCD | |
| SCHEMBL3589385 | 0.76 | MLYCD (0.48) | MLYCD | |
| SCHEMBL3188826 | 0.75 | NOS1 (0.46) | MLYCD | |
| SCHEMBL2469989 | 0.73 | MLYCD (0.46) | MLYCD | |
| SCHEMBL1512402 | 0.72 | MLYCD (0.48) | MLYCD | |
| SCHEMBL5875565 | 0.71 | NOS1 (0.42) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921576-B2 | Spiroindoline compound, and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| EP-2781521-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-8357679-B2 | Hexafluoroisopropanol derivatives | MSD OSS B.V. (NL) | 2013-01-22 | — | — | US | disclosed |
| US-8119819-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | disclosed |
| EP-2297118-B1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| CN-101596191-B | Method for treatment of disease using malonyl-coa decarboxylase inhibitor | CHUGAI PHARMACEUTICAL CO LTD | 2011-06-15 | — | — | CN | disclosed |
| EP-1411929-B1 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2297118-A1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES | N.V. Organon (NL) | 2011-03-23 | — | — | EP | disclosed |
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-21 | — | — | US | disclosed |
| CN-101596191-A | Malonyl coa decarboxylase inhibitor as metabolism regulators | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-12-09 | — | — | CN | disclosed |
| WO-2009138438-A1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES | N.V. ORGANON (NL) | 2009-11-19 | — | — | WO | disclosed |
| CN-100528154-C | Malonyl-COA decarboxylase inhibitors useful as metabolic modulators | CHUGAL SEIYAKU K K (JP) | 2009-08-19 | — | — | CN | disclosed |
| US-7524969-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-28 | — | — | US | disclosed |
| CN-1537001-A | Malonyl-COA decarboxylase inhibitors useful as metabolic modulators | ������ҩ��ʽ���� | 2004-10-13 | — | — | CN | disclosed |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | GCKR, GCK, GALK1 | MLYCD 1391/4885 |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | MLYCD 1/4885 |
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | FFAR2, FFAR3, FFAR1 | MLYCD 1602/4885 |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ME3, ACACA | MLYCD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.